Who are Reduced dose of DOAC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban, Rivaroxaban, dabigatran, apixaban, or edoxaban, Full dose of DOAC, Direct oral anticoagulant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reduced-dose-of-doac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Reduced dose of DOAC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduced dose of DOAC (Reduced dose of DOAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct Oral Anticoagulant (DOAC). Area: Cardiovascular.

phase 3 Direct Oral Anticoagulant (DOAC) Factor Xa or Factor IIa (thrombin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Reduced dose of DOAC (Reduced dose of DOAC) — University Hospital, Brest. A reduced dose of a direct oral anticoagulant (DOAC) inhibits specific coagulation factors to prevent thrombus formation while minimizing bleeding risk through dose optimization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reduced dose of DOAC TARGET	Reduced dose of DOAC	University Hospital, Brest	phase 3	Direct Oral Anticoagulant (DOAC)	Factor Xa or Factor IIa (thrombin)
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Rivaroxaban, Dabigatran	Rivaroxaban, Dabigatran	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran)
Dabigatran; Rivaroxaban	Dabigatran; Rivaroxaban	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa
Rivaroxaban, dabigatran, apixaban, or edoxaban	Rivaroxaban, dabigatran, apixaban, or edoxaban	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)
Full dose of DOAC	Full dose of DOAC	University Hospital, Brest	phase 3	Direct oral anticoagulant (DOAC)	Factor Xa or Factor IIa (thrombin)
Direct oral anticoagulant	Direct oral anticoagulant	Centre Hospitalier Universitaire de Nīmes	phase 3	Direct oral anticoagulant (DOAC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct Oral Anticoagulant (DOAC) class)

University Hospital, Brest · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reduced dose of DOAC — Competitive Intelligence Brief. https://druglandscape.com/ci/reduced-dose-of-doac. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab